Study on the Correlation Factors on CD44+CD24-/LowESA+Lin- Cell Ratio in Breast Cancer

WANG Rong, YANG Xiao-qin, LÜ Qing

Abstract

To explore the related factors on CD44+CD24-/LowESA+Lin- cell (breast caner stem cell) ratio in breast cancer patients. Methods?Flow cytometry was used to analyze CD44+CD24-/LowESA+Lin- cell ratio in fresh tumor tissues of 40 breast cancer patients administered between March of 2011 and January of 2012 in West China Hospital, Sichuan University, China. Nine individual variables, such as age, clinical stage, histological grade, axillary lymph nodes metastases, immunohistochemisty (IHC) of estrogen receptor (ER), progesterone receptor (PR), C-erbB-2, and Ki-67 were selected to study their correlation with CD44+CD24-/LowESA+Lin- cell ratio. Results?CD44+CD24-/LowESA+Lin- cells were expressed in all breast cancer tissues (median ratio: 4.38%, ranging from 0.5% to 16.8%), in which 20 patients (50.0%) showed low expression less than or equal to 4.38%, whereas, 20 patients (50.0%) demonstrated high expression greater than 4.38%. By univariant analysis, no statistical correlation was observed between CD44+CD24-/LowESA+Lin- cell ratio and the factors like age, tumor size, clinical stage, histological stage, axillary nodes metastasis metastasic, ER, PR. However, when Ki-67 was divided into high expression group (＞32.0%) and low expression group (≤32.0%), statistical difference in CD44+CD24-/LowESA+Lin- cell ratio between the two groups was observed (P=0.008). By multivariate logistic analysis, only Ki-67 expression was the independent factor of breast cancer stem cell expression (P=0.012, OR=6.926, (95%CI,1.529-31.377). Conclusion?In fresh breast cancer tissues, Ki-67 expression was the independent impact factor on CD44+CD24-/LowESA+Lin- cell ratio. Further investigation should be made to explore the correlation of breast cancer stem cell ratio with therapeutic effect and prognosis.

 

Keywords: Breast cancer, Cancer stem cells, Flow cytometry 

 

Full Text:

PDF


References


Ahmedin J, Rebecca S, Elizabeth W, et al. Cancer statistics. CA Cancer J Clin,2009;59(4) ;225-249.

Tiffany MP. William HM, Frank P. The response of CD24-/Low/CD44+breast cancer-initiating cells to radiation. J Nat Cancer Ins,2006;98(24);1777-1785.

Hai ZL, Tong BY, Zheng YW. Suspension culture combined with anticancer regimens for screening breast cancer stem cells. Med Hypotheses,2007;68(5);988-990.

Liu C, Luo Y, Liu X, et al. Clinical implications of CD44 + / CD24- tumor cell ratio in breast cqancer. Cancer Biother Radiopharm,2012; 27( 5): 324-328.

Dario P, Aurora C, Nadia Z, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/ progenitor cell properties. Cancer Res* 2005; 65 ( 13): 5506- 5511.

Al-Hajj М» Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A,2003; 100(7):3983-3988.

Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. Clin Oncol, 2005; 23( 28) : 7212- 7220.

Bonnet D, Dickj E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med, 1997;3(7) ;730-737.

Michael D, Tito F. Susan B. Tumor stem cells and drug resistence. Cancer,2005;4(5);275-284.

Singh SK. Clarke ID. Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res, 2003; 63 (18);5821-5828.

Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer, 1983; 31 ( 1) ; 13-20.

Lopez F. Belloc F. Lacombe F, et al. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry, 1991; 12( 1);42-49.

Ander U, Smith IE, Mitch D. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol,2005;23(28) ;7212-7220.

Chang J, Ormerod M, Powles TJ, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer,2000;89(11) ;2115-2152.


Refbacks

  • There are currently no refbacks.